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A B S T R A C T
Background
Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and
medical visits. Poorly controlled asthma often leads to preventable exacerbations that require additional medications, hospital stays, or
treatment in the emergency department.
Long-acting beta2-agonists (LABA) are the preferred add-on treatment for children with asthmawhose symptoms are not well controlled
on inhaled corticosteroids (ICS). TheUS Food and Drug Administration has issued a ’black box’ warning for LABA in asthma, and now
recommends that they be used “for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if
possible, once asthma control is achieved”.
Objectives
To compare the effect on asthma control and adverse effects of stepping down to inhaled corticosteroids (ICS)-only therapy versus
continuing ICS plus LABA in children whose asthma is well controlled on combined ICS and LABA therapy.
Search methods
We searched the Cochrane Airways Group Specialised Register, and also searched www.ClinicalTrials.gov, www.who.int/ictrp/en/,
reference lists of primary studies and existing reviews, and manufacturers’ trial registries (GlaxoSmithKline and AstraZeneca). We
searched all databases from their inception to the present, and imposed no restriction on language of publication. The most recent
search was done in April 2015.
Selection criteria
We looked for parallel randomised controlled trials of at least eight weeks’ duration, available as published full text, abstract only, or
unpublished data.We excluded studies including participants with other chronic respiratory comorbidities (for example bronchiectasis).
We looked for studies in which children (18 years or younger) whose asthma was well controlled on any dose of ICS and LABA
combination therapy were randomised to: a) step-down therapy to ICS alone or b) continued use of ICS and LABA.
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We included any dose of LABA (formoterol, salmeterol, vilanterol) and any dose of ICS (beclomethasone, budesonide, ciclesonide,
mometasone, flunisolide, fluticasone propionate, fluticasone furoate, triamcinolone) delivered in a combination inhaler or in separate
inhalers.
Data collection and analysis
Two review authors independently screened all records identified in the searches. We used a data extraction tool in Microsoft Excel to
manage searches and document reasons for inclusion and exclusion, and to extract descriptive and numerical data from trials meeting
the inclusion criteria.
The prespecified primary outcomes were exacerbations requiring oral steroids, asthma control, and all-cause serious adverse events.
Main results
Despite conducting extensive searches of electronic databases, trial registries andmanufacturers’ websites we identified no trials matching
the inclusion criteria.
After removing duplicates, we screened 1031 abstracts, and assessed 43 full-text articles for inclusion. We identified several adult studies,
which will be summarised in a separate review (Ahmad 2014). The most common reasons for exclusion after viewing full texts were
’wrong comparison’ (n = 22) and ’adult population’ (n = 18).
Some adult studies recruited adolescents from age 15, but none reported data separately for those under 18.
Authors’ conclusions
There is currently no evidence from randomised trials to inform the discontinuation of LABAs in children once asthma control is
achieved with ICS plus LABA. It is disappointing that such an important issue has not been studied, and a randomised double-blind
trial recruiting children who are controlled on ICS plus LABA is warranted. The study should be large enough to assess children of
different ages, and to measure the important safety and efficacy outcomes suggested in this review over at least six months.
The only randomised evidence for stopping LABA has been conducted in adults; it will be summarised in a separate review.
P L A I N L A N G U A G E S U M M A R Y
Stopping long-acting beta2-agonists for children well controlled on combination therapy
Background
Asthma is the most common long-term medical condition in children. Poorly controlled asthma often leads to flare-ups that require
extra treatment, hospital stays, or treatment in the emergency department.
Long-acting beta2-agonists (LABA) are an inhaled treatment that can be added to inhaled corticosteroids (ICS) for children with asthma
whose symptoms are not well controlled on ICS alone. The US Food and Drug Administration issued a warning for the use of LABA
in asthma after serious safety concerns emerged, and now recommends that they be used for the shortest time possible, and stopped
when the child’s asthma improves.
Review question
We looked for studies comparing a group of children who stopped taking their LABA with a group who continued taking ICS plus
LABA. We were mainly interested in whether there is an effect on asthma control and side effects of stopping LABA.
Studies had to be at least eight weeks’ long and include children whose asthma was well controlled on any dose of ICS plus LABA.
Two review authors independently screened all records found in the searches, which were done in April 2015.
Results
We found no studies matching the criteria above.
We screened 1031 records and read the full text of 43 articles we thought looked relevant, but could include none. We found several
adult studies, which will be summarised in a separate review (Ahmad 2014).
Some adult studies included adolescents from age 15, but none reported data separately for those under 18.
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Conclusion
There is currently no evidence from randomised studies looking at stopping LABA in children whose asthma is well controlled on ICS
plus LABA, which is disappointing given the importance of the question.
We will summarise studies in adults in a separate review (Ahmad 2014).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Stopping long-acting beta2-agonists (LABA) compared with continuing inhaled corticosteroids (ICS) + LABA for children with well-
controlled asthma
Patient or population: children (aged 18 years or younger) whose asthma is well controlled on combination ICS + LABA
Settings: outpatient
Intervention: stopping LABA
Comparison: continuing ICS + LABA
Outcomes No of Participants
(studies)
Comments
Exacerbations requiring systemic corticos-
teroids
0 (0) No studies met the inclusion criteria for the review
Asthma control (validated scales) 0 (0)
Serious adverse events (all cause) 0 (0)
Quality of life (validated scales) 0 (0)
Exacerbations requiring hospitalisation or
emergency department visit
0 (0)
Adverse events (all cause) 0 (0)
Withdrawals 0 (0)
B A C K G R O U N D
Description of the condition
Asthma is a long-term respiratory condition that causes difficulty
breathingdue tonarrowingof the airways, thickening of the airway
walls, andmucus buildup. Symptoms include wheezing, shortness
of breath, chest tightness, and cough that vary over time in their
occurrence, frequency, and intensity (GINA 2014).
Asthma is the most common chronic medical condition among
children and is one of the most common causes of hospitalisa-
tion and medical visits in children (PHAC 2007). The condition
frequently goes undiagnosed and untreated, and the direct treat-
ment costs together with indirect costs associated with lost pro-
ductivity are among the highest for non-communicable diseases
(Global Asthma Report 2011). Recent estimates suggest that 235
million people are affected worldwide, and this figure continues to
rise in low- and middle-income countries (Global Asthma Report
2011). Prevalence has been linked to various factors including air
pollution, tobacco legislation, diet, and prevalence of other atopic
diseases (Anderson 2005).
The two main aims of asthma treatment are daily control of symp-
toms and prevention of asthma attacks, or ’exacerbations’. These
can usually be achieved in progressive treatment ’steps’, depending
on the severity and frequency of symptoms (Australian Asthma
Handbook 2014; BTS/SIGN 2012; GINA 2014; NAEPP 2007).
Many children with asthma have intermittent symptoms that can
be managed with as-needed medications (for example salbuta-
mol), but some require regular treatment with inhaled corticos-
teroids (ICS) alone or in combination with other longer-acting
bronchodilator medications (GINA 2009; GINA 2014). Poorly
controlled asthma is a significant burden on health services, often
leading to preventable exacerbations that require additional medi-
cations, hospital stays, or treatment in the emergency department
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to bring symptoms back under control (BTS 2011). A recent UK
inquiry into asthma deaths in 2012 and 2013 found that there
was an association between mortality and avoidable factors such
as poor compliance to regular medications (48%) and overuse of
short-acting beta2-agonists (39%) (NRAD 2014).
Description of the intervention
The initial starting therapy for asthma is as-needed reliever (bron-
chodilator) inhalers such as salbutamol or terbutaline; this is com-
monly referred to as step 1 therapy. ICS is the preventer therapy
primarily recommended for people with persistent asthma who
do not gain sufficient control from as-needed reliever medica-
tions; this is step 2 therapy (Australian Asthma Handbook 2014;
BTS/SIGN 2012; GINA 2014). Regular use of ICS has been
shown to improve lung function and reduce the need for reliever
medications (Adams 2005; Adams 2009); however, a subset of
people have asthma that remains uncontrolled on ICS alone. In
addition, the dose-response relationship of regular ICS is not well
established in children (Zhang 2011).
Beyond step 2, national treatment guidelines recommend long-
acting beta2-agonists (LABA) as the preferred add-on therapy to
ICS when a person does not achieve asthma control on ICS and
short-acting reliever medication (Australian Asthma Handbook
2014; BTS/SIGN2012;GINA2014). Evidence from randomised
trials has shown that LABA add-on to ICS has significant benefits
for lung function, reliever use, and frequency of exacerbations
for adults whose asthma is not well controlled and that this is
preferable to increasing the ICS dose in adults (Ducharme 2010).
However, for children, the benefits of adding a LABA are less clear (
Ducharme 2008; Lemanske 2011); increasing the ICSdosemay be
more practical than adding a new medication. A Cochrane review
showed that the addition of LABA to ICS in children was not
associated with a significant reduction in the rate of exacerbations
requiring systemic steroids, but was superior for improving lung
function compared to the same dose of ICS alone (Ni Chroinin
2009).
In terms of safety, large adult surveillance studies and meta-anal-
yses of randomised trials have shown a link between LABA and
increased asthma morbidity and mortality (Cates 2014; Nelson
2006; Salpeter 2006). Evidence in children is less clear due to a
lack of similarly sized surveillance studies (Cates 2012b), but it
has been suggested that the risk of adverse asthma events may
be greater for children, especially those aged 4 to 11 (McMahon
2011). It is not yet known whether either of the two most widely
used LABAs, formoterol and salmeterol, is safer than the other for
children with asthma (Cates 2012b).
In 2010, the US Food and Drug Administration (FDA) issued a
’black box’ warning for LABA, the strictest warning put on the
labelling of prescription drugs when there is reasonable evidence
of an association with a serious hazard. The warning was issued
after the FDA’s analyses of clinical trials showed an “increased risk
of severe worsening of asthma symptoms, leading to hospitalisa-
tion in both children and adults and death in some patients with
asthma” (FDA 2010). Alongside the existing safety recommenda-
tions, the FDA has since required that manufacturers’ labels state
that LABA should only be used “for the shortest duration of time
required to achieve control of asthma symptoms and discontin-
ued, if possible, once asthma control is achieved”. The FDA has
since mandated large-scale clinical trials to assess the risks associ-
ated with LABA, which are currently under way, including a trial
in children (NCT01462344).
Other reviews including meta-analysis of non-randomised trials
have suggested that the risks of LABA may have been overstated
and that the benefits outweigh the risks for the majority of pa-
tients, perhaps because several older studies have allowed the use of
LABA as monotherapy (Hernández 2014; Oppenheimer 2008).
This field of thought suggests that a blanket warning for LABA
may actually be harmful to patients who are well controlled on
ICS plus LABA, and that research should focus on identifying the
subset of patients who might be at risk.
How the intervention might work
ICS reduce mucus buildup and exacerbations by reducing inflam-
mation in the airways (Barnes 1993); they can be taken once (flu-
ticasone furoate) or twice (beclomethasone, budesonide, flutica-
sone propionate) daily. LABA act as a bronchodilator by relax-
ing bronchial wall smooth muscle and can also be taken once (vi-
lanterol) or twice (formoterol, salmeterol) daily (Nelson 1995).
The use of LABA and ICS in combination can allow for lower
steroid doses to be used,which is important tominimise side effects
of steroid use in childhood such as growth suppression (Pruteanu
2014;Zhang 2014).However, beta2-agonists carry their own risks,
and there has beenmuch debate regarding the possible causal links
between their use and increased mortality and morbidity (Cates
2012a; Tattersfield 2006). Theories of beta2-agonist-related death
and adverse events include direct toxicity of the drugs themselves,
in particular their cardiac effects(Brown 1983); reduced response
to beta2-agonists over time causing a gradual worsening of disease
(Lipworth 1997); and delay in receiving medical help due to the
masking of underlying inflammation, known as the delay hypoth-
esis (Bijl-Hofland 2001). It has also been suggested that the delay
hypothesis is linked to a reduction in compliance with appropriate
ICS treatment (Johnston 2009), although this is less of an issue
since the introduction of combination inhalers. Confounding by
severity, in the sense that people with more severe disease are likely
to be taking LABA, has now been dismissed, since it cannot ex-
plain the overall increase in mortality in the 1960s and 1970s and
evidence from large case-control studies of beta2-agonists (Crane
1989).
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Why it is important to do this review
Despite the established evidence of safety concerns associated with
the use of LABA in uncontrolled asthma for adults, evidence for
the safety and efficacy of LABA is less well established for chil-
dren. Furthermore, there is limited evidence to support or guide
LABA discontinuation in adults or children once asthma control
is achieved with ICS plus LABA. The optimal duration of ICS
plus LABA therapy, or at what point to step down treatment once
good symptom control has been achieved, is not yet known.While
it has been shown that the detrimental effects of regular LABA
use are less marked when used in combination with ICS (Cates
2012b; Ernst 2006), and particularly with a combination inhaler
(FDA 2010), evidence from a Cochrane review was not able to
conclude whether the risk of adverse events remains higher than
with ICS alone (Ducharme 2008). Reviews have suggested that
the effects of adding LABA to ICS in children are different when
compared to adults (Ducharme 2010)
There are a variety of possible reasons why the risk-benefit ratio
of LABA may be different in adults compared with children and
adolescents, including age-related changes in pathophysiology and
phenotypes (Bush 2009), as well as being numerous phenotypes
within the paediatric age range (Spycher 2010). There are also
challenges associated with diagnosis, monitoring tests, and taking
medications that are specific to younger people, which warrant
addressing the two populations separately.
O B J E C T I V E S
To compare the effect on asthma control and adverse effects of
stepping down to ICS-only therapy versus continuing ICS plus
LABA in children whose asthma is well controlled on combined
ICS plus LABA therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewere interested in parallel randomised controlled trials (RCTs)
of at least eight weeks’ duration. We included studies reported as
full text, those published as abstract only, and unpublished data.
We did not include cross-over trials, as they were not suitable for
the assessment of long-term outcomes.
Types of participants
We looked for studies of children aged17or youngerwhose asthma
was well controlled with maintenance LABA and ICS. We pre-
specified that participants’ asthma control should be classified ac-
cording to prespecified criteria, for example below a score of 1.5
on the Asthma Control Questionnaire or the criteria for control
described in GINA 2014 guidelines (that is daytime symptoms
twice or less per week, need for rescue inhaler twice or less per
week, no nocturnal symptoms, and no limitation to daily activi-
ties).
If studies included both children and adults, we would only have
included the subset of relevant participants if the study authors
had been able to provide disaggregated data for participants who
fit the inclusion criteria. We excluded studies including partici-
pants with other chronic respiratory comorbidities (for example
bronchiectasis).
Types of interventions
We looked for studies in which children whose asthma was well
controlled on any dose of ICS plus LABA combination therapy
were randomised to step-down therapy to ICS alone (continued at
the same dose received prior to randomisation) versus continued
use of ICS and LABA (any preparation at the same dose received
prior to randomisation).
We included any dose of LABA (formoterol, salmeterol, vi-
lanterol) and any dose of ICS (beclomethasone, budesonide, ci-
clesonide, mometasone, flunisolide, fluticasone propionate, flu-
ticasone furoate, triamcinolone) delivered in a combination in-
haler or in separate inhalers. We included studies that gave a
different ICS in the intervention group, provided it was at the
same beclomethasone dipropionate equivalent dose as the ICS re-
ceived prior to stopping LABA, as this may reflect what happens
in practice (for example replacing salmeterol/fluticasone with be-
clomethasone).
One possible treatment strategy in asthma is to reduce the dose
of both LABA and ICS concurrently once asthma control has
been achieved (rather than stopping LABA); however, we did not
include studies addressing the effect of this intervention, as this is
a separate clinical question.
We included trials that allowed short-acting reliever medications,
provided they were not part of the randomised treatment.
Types of outcome measures
Primary outcomes
1. Exacerbations requiring systemic corticosteroids
2. Asthma control* (measured on a validated scale, e.g.
Asthma Control Questionnaire)
3. Serious adverse events (all cause)
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Wechose the primary outcomes to represent an importantmeasure
of resource use, a patient-important outcome, and a measure of
safety.
Secondary outcomes
1. Quality of life* (measured on a validated scale, e.g. Asthma
Quality of Life Questionnaire)
2. Exacerbations requiring hospitalisation or emergency
department (ED) visit
3. Adverse events (all cause)
4. Withdrawals
Reporting one or more of the outcomes listed here in the trial was
not an inclusion criterion for the review.
*Ifmore than one scalemeasuring the same construct was reported
within a study, or if different scales were used across studies, we
planned to analyse them using standardised mean difference.
If trials reported exacerbations as a composite that was not listed
(for example hospitalisation or ED visit or systemic corticos-
teroids), we planned to analyse these separately.
If we identified any economic evaluations based on RCTs that
make the comparison of interest in the main search, we sum-
marised them narratively to supplement the main systematic re-
view of effects.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group’s Spe-
cialisedRegister (CAGR), which ismaintained by the Trials Search
Co-ordinator for the Group. The CAGR contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals and meet-
ing abstracts (see Appendix 1 for further details). We searched all
records in the CAGR using the search strategy in Appendix 2.
We also conducted
searches of ClinicalTrials.gov (www.ClinicalTrials.gov), theWorld
Health Organization (WHO) trials portal (www.who.int/ictrp/
en/), and manufacturers’ trial registries (GlaxoSmithKline and As-
traZeneca).We searched all databases from their inception to April
2015, and imposed no restriction on language of publication.
Searching other resources
We checked reference lists of any relevant primary studies and re-
view articles for additional references. We searched relevant man-
ufacturers’ websites for trial information.
If included studies were found, we searched for errata or retrac-
tions published in full text on PubMed (www.ncbi.nlm.nih.gov/
pubmed).
Data collection and analysis
The following sections detail the methods we planned to use
had we identified any included studies. With the exception of
’Selection of studies’, we could not carry out any of the planned
methods of data extraction, ’Risk of bias’ assessment, and analysis
for this version, but have left them intact for updates of the review
in case future trials are identified.
Selection of studies
One review author (KK) and the author of the equivalent adult
review (SA) independently screened titles and abstracts identified
by the searches for inclusion in the review. We coded results as ’re-
trieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’.
We obtained the full-text study reports or publications, and two
review authors (KK and SA or SB) independently screened the full-
texts to identify studies for inclusion. We identified and recorded
reasons for exclusion of the ineligible studies, resolving any dis-
agreements through discussion or by consulting a third person
(SA or SB). We identified and excluded duplicates and collated
multiple reports of the same study so that each study, rather than
each report, was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram (Figure 1) and ’Characteristics of excluded studies’ table.
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Figure 1. Results of the search and study selection process
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Data extraction and management
If we can include studies in future updates, we will use a Microsoft
Excel data collection form for study characteristics and outcome
data that has been piloted on previous reviews. One review author
(KK) will extract the following study characteristics from included
studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
5. Notes: funding for trial and notable conflicts of interest of
trial authors
Two review authors (KK and SB) will independently extract out-
come data from included studies, noting in the ’Characteristics
of included studies’ table if outcome data were not reported in a
usable way. We will resolve any disagreements by consensus or by
involving a third person (SA). One review author (KK) will trans-
fer data into the RevMan (Review Manager 2014) file, double-
checking that data are entered correctly by comparing the data
presented in the systematic review with the study reports. A sec-
ond review author (SB) will spot-check study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (KK and SB) will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
resolving any disagreements by discussion or by involving a third
person (SA). We will assess the risk of bias according to the fol-
lowing domains:
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We will grade each potential source of bias as high, low, or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies
for each of the domains listed. We will consider blinding sepa-
rately for different key outcomes where necessary (for example for
unblinded outcome assessment, risk of bias for all-cause mortal-
ity may be very different than for a patient-reported pain scale).
Where information on risk of bias is related to unpublished data
or correspondence with a study author, we will note this in the
’Risk of bias’ table.
Where there are uncertainties due to insufficient reporting, we will
contact the study author or sponsor for additional information.
When considering treatment effects, we will take into account the
risk of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
Where possible, we conducted the review according to this pub-
lished protocol and have reported any deviations from it in the
’Differences between protocol and review’ section of the system-
atic review.
Measures of treatment effect
Wewill follow themethods below for future updates of this review
if we identify randomised trials.
We will analyse dichotomous data as odds ratios and continuous
data as mean difference or standardised mean difference. We will
enter data presented as a scale with a consistent direction of effect
and narratively describe skewed data reported as medians and in-
terquartile ranges.
We will undertake meta-analyses only where this is meaningful,
that is if the treatments, participants, and the underlying clinical
question are similar enough for pooling to make sense.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (for example
drug A versus placebo and drug B versus placebo) were combined
in the same meta-analysis, we will half the control group to avoid
double-counting.
If change from baseline and endpoint scores are available for con-
tinuous data, we will use change from baseline unless the majority
of studies report endpoint scores. If a study reports outcomes at
multiple time points, we will use the end-of-study measurement.
When an analysis using only participants who completed the trial
and an analysis that imputed data for participants who were ran-
domised but did not provide endpoint data (for example last ob-
servation carried forward) are both available, we will use the latter.
Unit of analysis issues
For dichotomous outcomes, we will use participants rather than
events as the unit of analysis (that is number of children admitted
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to hospital rather than number of admissions per child). However,
if exacerbations are reported as rate ratios, we will also analyse
them on this basis.
Dealing with missing data
If we can include studies in future updates, we will contact inves-
tigators or study sponsors to verify key study characteristics and
obtain missing numerical outcome data where possible (for exam-
ple when we identify a study as abstract only). Where this is not
possible, and the missing data are thought to introduce serious
bias, we will explore the impact of including such studies on the
overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity, we
will report it and explore possible causes by prespecified subgroup
analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small-study and publication
biases. We will consider the impact of unpublished trials in the
GRADE ratings for each outcome.
Data synthesis
If we can include studies in future updates, we will use a random-
effects model for all analyses, as we expect variation in effects due
to differences in study populations and methods. We will perform
sensitivity analyses with a fixed-effect model.
’Summary of findings’ table
While there were no included studies, we created a Summary of
findings for the main comparison to illustrate the lack of evidence
for the seven prespecified outcomes. If we can include studies in
future updates, wewill present the pooled analysis in each case, and
note any significant differences between subgroups in the com-
ments column.We will use the five GRADE considerations (study
limitations, consistency of effect, imprecision, indirectness, and
publication bias) to assess the quality of a body of evidence as it
relates to the studies that contribute data to the meta-analyses for
the prespecified outcomes. We will use methods and recommen-
dations described in Section 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventionsusing GRADEpro
software (Higgins 2011). We will justify all decisions to down- or
upgrade the quality of studies using footnotes, and we will make
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
If we identify trials in future updates of this review, we will carry
out the following subgroup analyses for the primary outcomes,
using the formal test for subgroup differences in Review Manager
2014:
1. Mean steroid dose (defined as low, medium, and high
cutoffs according to GINA 2014)
2. Type of inhaler used in the comparison group (ICS plus
LABA combination inhaler versus separate inhalers)
3. Type and dose of LABA being stopped (formoterol,
salmeterol, vilanterol)
Mean steroid dose of the population in each study may reflect
differences in disease severity and may have an effect on outcomes
after stopping LABA therapy. We will use the boundaries for low,
medium, and high dose (ex-actuator) described in GINA 2014.
Participants using combination inhalers might be less likely to ex-
perience potential adverse effects of LABA treatment, since there is
no danger of taking the LABA inhaler without ICS. Combination
inhalers may also be associated with generally better compliance
with treatment.
There may be differences in stopping different types of LABA
due to their different pharmacological properties and durations of
action.
Sensitivity analysis
Wewill carry out the following sensitivity analyses for the primary
analyses, by excluding the following:
1. Studies at high risk of bias for blinding
2. Unpublished data (i.e. no peer-reviewed full paper available)
R E S U L T S
Description of studies
Results of the search
We retrieved 400 records in themain database search, and searches
of the additional resources (clinicaltrials.gov, WHO trials portal,
reference lists, and drug company registries) returned a total of 634
records. After removing duplicates, we screened 1031 references.
We excluded 988 from the title and abstracts alone. We assessed
43 full-text articles (belonging to 23 studies) for inclusion in either
this review or the equivalent adult review, which is being produced
in parallel. Of these, 22 made the wrong comparison, 16 were
adult studies and were included in the respective review, and 4
were classified as ongoing studies or studies awaiting classification
in the adult review. The one remaining study was a single-group
observational study.
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Included studies
No studies met the inclusion criteria.
Excluded studies
We excluded 23 studies (44 citations), mostly because the com-
parison was incorrect (n = 22) or an adult population was studied
(n = 18).
Studies were excluded due to wrong comparison usually because
they tested ICS plus LABA against LABA, but were not assessing
the question of stopping LABA in a well-controlled population.
Of the studies excluded due to the population age but meeting all
other inclusion criteria, several included adolescent participants
(from 15 or 16 years of age) but did not report data separately for
those under 18 (Berger 2010; GSK SAS40037; Koenig 2008).
We excluded three records because their study design did not
meet the inclusion criteria: one adult cross-over study with two
associated citations and one study asking the right clinical ques-
tion in children using a single-group observational design (GSK
SMS30046; NTR2045).
We identified one other study recruiting adults and adolescents
from age 12 and with a planned enrolment of 450 on clinicaltri-
als.gov and recorded it as an ongoing study (NCT01437995). We
hope we can obtain disaggregated data for the adolescents in this
study when the results are published.
Risk of bias in included studies
There were no included studies to assess for risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
There were no effects of interventions as no randomised trials met
the inclusion criteria.
D I S C U S S I O N
Summary of main results
We conducted extensive searches for trials that randomised chil-
dren with well-controlled asthma to either stop their LABA or to
continue taking combination ICS plus LABA.
Despite conducting extensive additional searches, we identified no
trials matching the inclusion criteria.
After removing duplicates, we screened 1031 abstracts and assessed
43 full-text articles for inclusion. We identified several adult stud-
ies, which have been summarised in a separate review. The most
common reason for exclusion after viewing full-texts were ’wrong
comparison’ and ’adult population’.
Of the studies excluded due to the population age but meeting all
other inclusion criteria, several included adolescent participants,
but did not report data separately for those under 18 (Berger 2010;
GSKSAS40037;Koenig 2008).One study asking the right clinical
question in children was identified on the WHO trials portal, but
it was a single-group observational design (NTR2045).
We identified one other study recruiting adults and adolescents
from age 12 and with a planned enrolment of 450 on clinicaltri-
als.gov and recorded it as an ongoing study (NCT01437995). We
hope we can obtain disaggregated data for the adolescents in this
study when the results are published.
Overall completeness and applicability of
evidence
We identified no trials making the specified comparison in chil-
dren, which represents an important evidence gap considering
the recommendations to stop LABA once control is achieved. It
is not clear why this important issue has not been addressed in
randomised trials, particularly as several have been conducted in
adults. Since we do not know how stopping LABA affects symp-
tom control or the likelihood of adverse outcomes in children, it
would be ethical to randomise children to stop or continue LABA
treatment. Randomised, double-blinded evidence from trials of
at least six months may prevent future adverse events and poor
asthma control by informing clinicians of the benefits and harms
of stopping LABA relative to continuing.
It is likely that future updates of this review will include data from
ongoing trials conducted in populations of adults and adolescents
with asthma. This evidence, if disaggregated data can be obtained,
will provide important information regarding the applicability of
adult evidence to younger populations. However, no published or
ongoing trials have yet included children younger than age 12,
and there may be different safety issues in this younger group of
people with asthma.
Quality of the evidence
We excluded no trials in this review, but we conducted compre-
hensive searches that two review authors sifted independently. We
excluded no trials for not meeting our inclusion criteria relating
to duration or comedications, and there were no disagreements
between review authors over their decisions to exclude. In line
with Cochrane methods, we excluded no trials on the basis of
language, publication status, or the outcomes reported, so we are
confident that we would have identified and included any relevant
randomised evidence.
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Potential biases in the review process
The Cochrane Airways Group’s Trials Search Co-ordinator de-
signed and conducted the main electronic search, and two review
authors discussed and sifted in duplicate additional searches. A
paediatrician (SB) with expert knowledge in the area reviewed the
potentially relevant records.
We did not attempt to obtain disaggregated data from the three
adult trials that met the inclusion criteria and included adolescents
between the age of 15 and 18. Since 15 and 16 were the lower age
limits in these trials, and the mean ages were between 38 and 41,
we concluded that the number of adolescent participants would be
small andnot necessarily representative of children and adolescents
in general.
Agreements and disagreements with other
studies or reviews
Two systematic reviews have assessed this question, but neither
were able to comment specifically on evidence for adolescents and
children. While one non-Cochrane review looked for studies in
adults and children (Brozek 2012), and a Cochrane review looked
solely for adult studies (Ahmad 2014), the two reviews included
the same five studies in meta-analysis and reached similar conclu-
sions. Brozek 2012 noted the lack of evidence for children and
the inclusion of older children and adolescents (15 years and over)
in several of the trials, but without individual participant data in
larger and longer trials, it is not possible to judge whether the
older children within the adult studies had different outcomes,
and there is no information for younger children.
Both reviews concluded that the evidence for adults and older
children suggests a clear loss of symptom control after stopping
LABA on several measures. Both reviews suggested that even the
evidence base for adults and older children is incomplete; there
were infrequent events for some of the most important outcomes
(for example exacerbations requiring hospital admission, serious
adverse events, and mortality), a small number of trials contribut-
ing to several of the meta-analyses, and relatively short follow-up
times. This paucity of evidence also precluded any meaningful
subgroup analyses to explore possible effect modifiers such as ICS
dose and type of LABA. There is a total lack of information for
children under 15 years of age.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence from randomised trials to inform
LABA discontinuation in children once asthma control is achieved
with ICS plus LABA.
The only randomised evidence for stopping LABA has been con-
ducted in adults, and will be summarised in a separate review
(Ahmad 2014). Evidence from an ongoing trial recruiting adults
and children over age 12 may provide some initial evidence for
older children.
Implications for research
A double-blind randomised trial to assess this question would help
clinicians judge when it is safe and beneficial to stop LABA in
children. The study should be large enough to assess children
of different ages, and measure the important safety and efficacy
outcomes suggested in this review over at least six months.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aalbers 2005 Wrong comparison - not stepping down LABA
Berger 2010 Wrong population - adults
Bumbacea 2010 Wrong comparison - not stopping LABA
Cowie 2007 Wrong comparison - not stopping LABA
FitzGerald 2003 Wrong comparison - not stopping LABA
Fowler 2002 Wrong comparison - ICS dose was higher in the step-down group
Godard 2008 Wrong population - adults
GSK ADA109315 Wrong comparison - not stopping LABA
Analysis of healthcare utilisation and costs of stepping down LABA
GSK SAS40037 Wrong population - adults
GSK SMS30046 Wrong study design - cross-over study
Harrison 1997 Wrong comparison - not stopping LABA
Ind 2004 Wrong comparison - not stopping LABA
Koenig 2008 Wrong population - adults
Liu 2007 Wrong population - adults
Nathan 2009 Wrong comparison - not stopping LABA
NCT00158834 Wrong comparison - not stopping LABA using symptom scores with or without PD20 methacholine to adjust
treatment
NCT01565031 Wrong comparison - no clear step-down strategy for LABA
NCT02094937 Wrong population - adults (ongoing trial)
NTR2045 Wrong study design - single-group observational study
The effect of stepping down from LABA/ICS combination therapy to ICS monotherapy on exercise and
mannitol challenge tests in asthmatic children
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(Continued)
Obase 2013 Wrong comparison - not stopping LABA
Paggiaro 2011 Wrong comparison - not stopping LABA
Papi 2012 Wrong comparison - not stopping LABA
Reddel 2010 Wrong population - adults
Self 1998 Wrong comparison - ICS stepped down
Shamsul 2007 Wrong comparison - two step-down groups
Slankard 2011 Wrong population - adults
Zangrilli 2009 Wrong comparison - ICS stepped down
Characteristics of ongoing studies [ordered by study ID]
NCT01437995
Trial name or title Long-acting Beta Agonist Step Down Study (LASST)
Methods 56-week, multicentre, blinded, randomised, double-masked parallel group comparative effectiveness study of
approaches to stepping down therapy for people with well-controlled asthma treated with combination ICS
and LABA
Participants Inclusion Criteria: males and females aged 12-80 years with well-controlled asthma on moderate dose ICS/
LABA based on an Asthma Control Test score≥ 20, absence of unscheduled visits or use of rescue prednisone
for 4 weeks prior to enrolment and a pre-bronchodilator FEV1 ≥ 70% predicted
Exclusion Criteria: chronic oral steroid therapy, hospitalisation or urgent care visit within 4 weeks of the
screening visit, lung disease other than asthma including COPD, bronchiectasis, sarcoidosis, or other lung
disease. Less than 10 pack/yr of tobacco use and abstinence, post-bronchodilator FEV1 < 70% predicted,
near fatal asthma (intubation or ICU admission for asthma) within 2 yrs of enrolment, high risk of near fatal
or fatal asthma, history of known premature birth less than 33 weeks or any significant level of respiratory
care including prolonged oxygen administration or mechanical ventilation during the neonatal period, un-
stable cardiac disease (decompensated congestive heart failure, unstable angina, recent myocardial infarction,
atrial fibrillation, supraventricular or ventricular tachycardia, congenital heart disease, or severe uncontrolled
hypertension), other major chronic illnesses, drug allergies, pregnancy, lactation
Interventions Stepping down from fluticasone/salmeterol Diskus 250/50 mcg twice a day to fluticasone Diskus 250 mcg
twice a day without salmeterol
Outcomes Primary: Rate of treatment failures (decline in peak flow or FEV1, increased need for beta agonists, require-
ment for non-scheduled medical care for asthma symptoms, or prednisone taper)
Secondary: Pulmonary function (morning peak expiratory flow, pre-bronchodilator FEV1), episodes of
poor asthma control defined by unscheduled medical care, hospitalisation, use of oral corticosteroids and/or
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NCT01437995 (Continued)
increased use of rescue medications and/or decrease of 30% or more in morning peak expiratory flow rate
Starting date March 2012
Contact information Joy Saams, Registered Nurse
Notes Estimated enrolment: 450. Estimated study completion date: June 2015
May be able to obtain data for children and adolescents separately from the adult participants
20Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search






Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
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(Continued)
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/









11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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Appendix 2. Search strategy to identify trial reports from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenergic beta-Agonists








#14 Seretide or Advair or Viani or Symbicort or Inuvair or Dulera or Adoair or Breo or Relvar







#22 (step-down or “step down”):ti,ab
#23 (reduc* or decreas*) NEAR (dose*):ti,ab
#24 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #4 and #15 and #24
[Note: in search line #1 MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
C O N T R I B U T I O N S O F A U T H O R S
ShaleenAhmad searched clinicaltrials.gov and drug company trial registries. ShaleenAhmad andKayleighKew sifted themain electronic
search and the results from additional searching, and compiled the study shortlist. Sean Beggs and Kayleigh Kewmade the final decisions
on study exclusion. Kayleigh Kew wrote up the draft manuscript with clinical and editorial appraisal from Sean Beggs.
D E C L A R A T I O N S O F I N T E R E S T
Kayleigh Kew: none known
Sean Beggs: none known
Shaleen Ahmad: none known
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
No trials met the inclusion criteria for this review, we were unable to conduct meta-analyses, implement any of the data analysis plan,
or conduct any of the planned subgroup or sensitivity analyses.
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